You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
|
|---|---|
| Published in |
OncoImmunology, May 2015
|
| DOI | 10.1080/2162402x.2015.1038011 |
| Pubmed ID | |
| Authors |
Paul J Neeson, Andy K Hsu, Yin R Chen, Heloise M Halse, Joanna Loh, Reece Cordy, Kate Fielding, Joanne Davis, Josh Noske, Alex J Davenport, Camilla A Lindqvist-Gigg, Robin Humphreys, Tsin Tai, H Miles Prince, Joseph A Trapani, Mark J Smyth, David S Ritchie |
| Abstract |
There is increasing evidence that some cancer therapies can promote tumor immunogenicity to boost the endogenous antitumor immune response. In this study, we used the novel combination of agonistic anti-TRAIL-R1 antibody (mapatumumab, Mapa) with low dose bortezomib (LDB) for this purpose. The combination induced profound myeloma cell apoptosis, greatly enhanced the uptake of myeloma cell apoptotic bodies by dendritic cell (DC) and induced anti-myeloma cytotoxicity by both CD8(+) T cells and NK cells. Cytotoxic lymphocyte expansion was detected within 24 h of commencing therapy and was maximized when myeloma-pulsed DC were co-treated with low dose bortezomib and mapatumumab (LDB+Mapa) in the presence of NK cells. This study shows that Mapa has two distinct but connected modes of action against multiple myeloma (MM). First, when combined with LDB, Mapa produced powerful myeloma cell apoptosis; secondly, it promoted DC priming and an NK cell-mediated expansion of anti-myeloma cytotoxic lymphocyte (CTL). Overall, this study indicates that Mapa can be used to drive potent anti-MM immune responses. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| United Kingdom | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 50% |
| Scientists | 3 | 38% |
| Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 4 | 24% |
| Other | 3 | 18% |
| Student > Bachelor | 1 | 6% |
| Professor | 1 | 6% |
| Student > Ph. D. Student | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 5 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 4 | 24% |
| Medicine and Dentistry | 3 | 18% |
| Agricultural and Biological Sciences | 2 | 12% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Decision Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 5 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2022.
All research outputs
#3,221,790
of 25,371,288 outputs
Outputs from OncoImmunology
#204
of 2,178 outputs
Outputs of similar age
#39,660
of 280,154 outputs
Outputs of similar age from OncoImmunology
#8
of 89 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,178 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,154 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.